Ulcerative Colitis trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Ulcerative Colitis. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month5 studies across 4 companies, in the next 180 days.
September 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ABBV | AbbVie | A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World SettingNCT07421258observationalPercentage of Participants Managed Using Treat-to-Target (T2T) | — | Recruiting | Sep 2026 | ≤ 41 d | 2026-03-27 |
December 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| SNY | Sanofi | A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative ColitisNCT06975722Proportion of participants who achieve clinical remission at the end of Week 16 by modified Mayo Score (mMS) | Phase 2 | Recruiting | 2026-12-17 | in 119 d | 2026-04-23 |
| ABBV | AbbVie | An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC)NCT06838845observationalAchievement of clinical response per partial adapted Mayo score. | — | Recruiting | Dec 2026 | ≤ 133 d | 2025-11-26 |
January 2027 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| GILD | Gilead Sciences | Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative ColitisNCT06029972Proportion of Participants Achieving Clinical Response Per Modified Mayo Clinic Score at Week 12 | Phase 2 | Recruiting | Jan 2027 | ≤ 164 d | 2026-02-11 |
| TCRX | TScan Therapeutics, Inc. | A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune DiseaseNCT06587828observationalIdentify peptide targets together with their associated TCRs in patients with autoimmune diseases under study. | — | Recruiting | Jan 2027 | ≤ 164 d | 2025-11-24 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Ulcerative Colitis
most recently updated first181 studies match. Showing the first 100 of 181 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | AbbVie | $457.5B | A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative ColitisNCT07071519PK Lead-In Cohort 1: Maximum Observed Serum Concentration (Cmax) | Phase 3 | Recruiting | Drug: Risankizumab, Risankizumab | Ulcerative Colitis | 120 | 2025-07-28 | Jul 2034 | ≤ 2,902 d | 2026-08-18 |
| SNY | Sanofi | — | A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative ColitisNCT07185009Pivotal Maintenance Sub-Study Cohort 1: Proportion of participants achieving clinical remission by modified Mayo Score (mMS). | Phase 3 | Recruiting | Drug: Duvakitug, Placebo | Ulcerative Colitis | 751 | 2026-01-16 | 2028-09-21 | in 763 d | 2026-08-18 |
| SYRE | Spyre Therapeutics, Inc. | $9.5B | Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBDNCT07652294Percentage of participants who experienced an adverse event | Phase 2 | Enrolling by invitation | Drug: SPY001, SPY002, SPY003 | Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative | 645 | 2026-06-08 | 2029-03-02 | in 925 d | 2026-08-18 |
| VNDA | Vanda Pharmaceuticals | $329M | Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative ColitisNCT07686081Clinical Remission at Week 16 | Phase 3 | Recruiting | Drug: Ponesimod, Placebo | Ulcerative Colitis (UC) | 150 | Sep 2026 | Apr 2029 | ≤ 984 d | 2026-08-18 |
| ABBV | AbbVie | $457.5B | Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative ColitisNCT07136116observationalTo assess the achievement of clinical remission per Partial Adapted Mayo Score of Risankizumab treatment in participants with moderate to severe Ulcerative Colitis (UC) | — | Recruiting | — | Ulcerative Colitis | 200 | 2025-10-09 | Feb 2030 | ≤ 1,288 d | 2026-08-14 |
| LLY | Eli Lilly and Company | $1.15T | A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)NCT04844606Percentage of Participants with UC in Modified Mayo Score (MMS) Clinical Remission | Phase 3 | Recruiting | Drug: Mirikizumab, Mirikizumab | Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease | 150 | 2021-05-26 | Dec 2030 | ≤ 1,594 d | 2026-08-07 |
| LLY | Eli Lilly and Company | $1.15T | Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyNCT06937086Percentage of Participants Who Simultaneously Achieve Clinical Remission and at Least 10% Weight Reduction | Phase 3 | Recruiting | Drug: Mirikizumab, Mirikizumab, Tirzepatide, Placebo | Ulcerative Colitis, Obesity or Overweight | 350 | 2025-06-26 | Apr 2028 | ≤ 619 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:NCT07186101Percentage of Participants Who Achieve Clinical Remission with Modified Mayo Score (mMS) | Phase 2 | Recruiting | Drug: LY4268989, Mirikizumab, LY4268989 Placebo | Ulcerative Colitis | 252 | 2025-11-10 | May 2027 | ≤ 284 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | LY4268989 in Adults With Moderately to Severely Active Ulcerative ColitisNCT07415044Percentage of Participants Who Achieve Clinical Remission with Modified Mayo Score (mMS) | Phase 2 | Recruiting | Drug: LY4268989, Placebo | Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe | 1,431 | 2026-03-26 | Jun 2030 | ≤ 1,410 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's DiseaseNCT07483073Number of Participants Allocated to Each of the Intervention-Specific Appendices (ISA) | Phase 2 | Recruiting | Drug: Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC), LY4395089 | Colitis, Ulcerative, Crohn Disease | 60 | 2026-05-04 | Jun 2027 | ≤ 314 d | 2026-08-06 |
| ABBV | AbbVie | $457.5B | A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to VedolizumabNCT06880744Percentage of Risankizumab Group Participants Achieving Endoscopic Improvement As Compared to The Vedolizumab Group | Phase 3 | Active, not recruiting | Drug: Risankizumab, Risankizumab, Vedolizumab | Ulcerative Colitis | 573 | 2025-06-17 | Aug 2027 | ≤ 376 d | 2026-08-04 |
| PFE | Pfizer | $155.3B | Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative ColitisNCT04624230Remission by central read Mayo score following 44 weeks in the maintenance phase. | Phase 3 | Active, not recruiting | Drug: tofacitinib | Ulcerative Colitis | 118 | 2021-08-12 | 2027-03-17 | in 209 d | 2026-08-03 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative ColitisNCT06598943Percentage of Participants Achieving Clinical Remission | Phase 2 | Recruiting | Drug: Eltrekibart, Mirikizumab, Placebo | Ulcerative Colitis, Ulcerative Colitis Chronic | 143 | 2024-10-10 | Dec 2027 | ≤ 498 d | 2026-07-30 |
| SYRE | Spyre Therapeutics, Inc. | $9.5B | A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative ColitisNCT07012395Part A: Change in Robarts Histopathology Index (RHI) | Phase 2 | Recruiting | Drug: SPY001, SPY002, SPY003 · Other: Placebo | Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative | 645 | 2025-05-27 | Jun 2027 | ≤ 314 d | 2026-07-28 |
| XNCR | Xencor, Inc. | $1.9B | Study of XmAb942 in Healthy Participants and Participants With Ulcerative ColitisNCT06619990Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of XmAb942 in healthy volunteers (Part A) | Phase 1/2 | Recruiting | Biological: XmAb942 · Drug: Placebo | Ulcerative Colitis (UC) | 270 | 2024-10-10 | Apr 2028 | ≤ 619 d | 2026-07-24 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative ColitisNCT05076175Proportion of participants who achieve clinical remission | Phase 2/3 | Recruiting | Drug: Ozanimod | Colitis, Ulcerative | 120 | 2022-05-30 | 2032-07-12 | in 2,153 d | 2026-07-23 |
| ABBV | AbbVie | $457.5B | Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative ColitisNCT05496348observationalPercentage of participants achieving symptomatic remission per partial adapted Mayo score among those who achieved clinical response and/or intestinal ultrasound (IUS) response at week 8 of upadacitinib (UPA) induction | — | Active, not recruiting | — | Ulcerative Colitis | 400 | 2022-10-20 | Aug 2027 | ≤ 376 d | 2026-07-16 |
| ABBV | AbbVie | $457.5B | Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative ColitisNCT07697456Crohn's Disease Specific: Percentage of Participants Achieving Endoscopic Remission | Phase 2 | Not yet recruiting | Drug: Risankizumab, Trosunilimab, ABBV-701 | Crohn's Disease, Ulcerative Colitis | 2,000 | 2026-07-24 | Oct 2031 | ≤ 1,898 d | 2026-07-13 |
| PFE | Pfizer | $155.3B | An Extension Study for Treatment of Moderately to Severely Active Ulcerative ColitisNCT03950232Number and Severity of Safety Measures | Phase 3 | Active, not recruiting | Drug: Etrasimod | Ulcerative Colitis | 896 | 2019-09-05 | 2029-06-19 | in 1,034 d | 2026-07-09 |
| PFE | Pfizer | $155.3B | An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative ColitisNCT06398626observationalProportion of patients with symptomatic remission | — | Recruiting | Drug: Etrasimod | Colitis, Ulcerative | 300 | 2024-09-17 | 2027-10-01 | in 407 d | 2026-07-09 |
| PFE | Pfizer | $155.3B | A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative ColitisNCT05287126Proportion of Participants Achieving Clinical Remission as Assessed by Modified Mayo Score (MMS) at Week 52 | Phase 2 | Recruiting | Drug: Etrasimod | Ulcerative Colitis | 36 | 2022-12-16 | 2029-06-16 | in 1,031 d | 2026-07-08 |
| ABVX | Abivax S.A. | — | ABTECT - MaintenanceNCT05535946Rate of subjects in clinical remission at Week 44 | Phase 3 | Active, not recruiting | Drug: ABX464, Placebo | Ulcerative Colitis | 1,116 | 2023-01-16 | 2026-04-28actual | — | 2026-07-07 |
| PFE | Pfizer | $155.3B | A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative ColitisNCT07470879Number and percent of enrolled participants with clinical remission based on Modified Mayo Score (MMS) at Week 52 | Phase 2 | Recruiting | Drug: Etrasimod | Colitis, Ulcerative | 24 | 2026-05-28 | 2030-09-08 | in 1,480 d | 2026-06-26 |
| AZN | AstraZeneca | — | Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative ColitisNCT03616821results2026-06-23Clinical Remission | Phase 2 | Terminatedsponsor's stated reason: Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease. | Drug: Brazikumab, Placebo | Ulcerative Colitis, IBD | 242 | 2018-08-07 | 2023-10-23actual | — | 2026-06-23 |
| AZN | AstraZeneca | — | Open-label Extension Study of Brazikumab in Ulcerative ColitisNCT04277546results2026-06-23Adverse Events | Phase 2 | Terminatedsponsor's stated reason: Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease. | Drug: Brazikumab Maintenance Dose, Brazikumab Induction Dose | Ulcerative Colitis | 57 | 2020-03-03 | 2023-10-10actual | — | 2026-06-23 |
| OSE.PA | OSE Immunotherapeutics | $87M | Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative ColitisNCT04882007results2026-06-23Change From Baseline in Modified Mayo Score (MMS) at Week 10 | Phase 2 | Completed | Drug: OSE-127, Placebo | Ulcerative Colitis | 136 | 2020-10-02 | 2024-04-30actual | — | 2026-06-23 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative ColitisNCT06294925observationalProportion of patients with symptomatic remission | — | Recruiting | Drug: Etrasimod | Colitis, Ulcerative | 360 | 2024-05-08 | 2026-06-30 | — | 2026-06-22 |
| ABBV | AbbVie | $457.5B | Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative ColitisNCT06764706observationalPercentage of Participants Achieving Symptomatic Remission Responder Per Partial Adapted Mayo Score | — | Recruiting | — | Ulcerative Colitis | 200 | 2025-02-27 | Jul 2028 | ≤ 711 d | 2026-06-18 |
| ABBV | AbbVie | $457.5B | Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative ColitisNCT05785715results2026-06-15Change From Baseline in Modified Mayo Score (MMS) at Week 12 | Phase 2 | Terminatedsponsor's stated reason: Sponsor Decision\_Not Safety Related | Drug: NX-13 250mg, NX-13 750mg, NX-13 Placebo | Ulcerative Colitis | 81 | 2023-04-24 | 2025-05-30actual | — | 2026-06-15 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their OffspringNCT05953402observationalEvent rate of Major Congenital Malformations (MCM) | — | Recruiting | — | Ulcerative Colitis | 1,182 | 2026-04-21 | 2034-06-30 | in 2,871 d | 2026-06-15 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative ColitisNCT05767021results2025-09-30Change From Baseline in Bowel Urgency Severity Urgency Numeric Rating Scale (UNRS) | Phase 3 | Completed | Drug: Mirikizumab, Mirikizumab | Ulcerative Colitis, Ulcerative Colitis Chronic | 172 | 2023-05-17 | 2024-08-09actual | — | 2026-06-10 |
| PFE | Pfizer | $155.3B | Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In SwedenNCT04338204observationalProportion of Participants in Remission as Measured by Partial Mayo Score | — | Completed | Drug: tofacitinib | Ulcerative Colitis | 102 | 2020-09-14 | 2025-09-30actual | — | 2026-06-03 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative ColitisNCT05784246Percentage of Participants with modified Mayo score (MMS) Clinical Remission at Week 52 among the Week 12 Clinical Responders | Phase 3 | Completed | Drug: Mirikizumab IV, Mirikizumab SC | Ulcerative Colitis | 63 | 2023-11-22 | 2026-05-01actual | — | 2026-06-03 |
| BMY | Bristol-Myers Squibb | $134.9B | Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative ColitisNCT07271069observationalProportion of participants achieving steroid-free symptomatic remission | — | Recruiting | Drug: Ozanimod, Azathioprine | Ulcerative Colitis (UC) | 150 | 2026-01-29 | 2027-03-31 | in 223 d | 2026-05-18 |
| PFE | Pfizer | $155.3B | An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative ColitisNCT07459686observationalThe incidence of serious infections (adverse events and adverse drug reactions) and safety specifications (adverse drug reactions) | — | Recruiting | Drug: Velsipity | Ulcerative Colitis (UC) | 553 | 2026-04-27 | 2029-01-29 | in 893 d | 2026-05-18 |
| ABBV | AbbVie | $457.5B | Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.NCT05782907Percentage of Participants Achieving Adapted Mayo score (AMS) Clinical Remission (Period 1) | Phase 3 | Active, not recruiting | Drug: Upadacitinib | Ulcerative Colitis | 122 | 2023-11-06 | Aug 2028 | ≤ 742 d | 2026-05-14 |
| PFE | Pfizer | $155.3B | Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis PopulationNCT07177209observationalProportion of patients that achieve early control of inflammation on conventional therapeutics within 6-24 months of UC diagnosis. | — | Active, not recruiting | Drug: Non-Interventional Study | Ulcerative Colitis | 4,000 | 2026-04-01 | 2026-07-31 | — | 2026-05-14 |
| LLY | Eli Lilly and Company | $1.15T | A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative ColitisNCT03524092results2022-11-25Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders) | Phase 3 | Completed | Drug: Mirikizumab SC, Mirikizumab IV, Placebo SC | Ulcerative Colitis | 1,328 | 2018-10-19 | 2021-11-03actual | — | 2026-05-13 |
| ABVX | Abivax S.A. | — | Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative ColitisNCT04023396results2025-04-27Proportion of Patients With Clinical Remission at Week 48 Compared to Baseline of Induction Study (ABX464-103) | Phase 2 | Completed | Drug: ABX464 | Ulcerative Colitis | 217 | 2020-01-13 | 2023-02-23actual | — | 2026-05-06 |
| ABVX | Abivax S.A. | — | Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative ColitisNCT05177835Number of adverse events in ABX464 treated subjects | Phase 2 | Active, not recruiting | Drug: ABX464 | Ulcerative Colitis | 203 | 2021-12-03 | Mar 2028 | ≤ 589 d | 2026-04-27 |
| SNY | Sanofi | — | An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative ColitisNCT07184996Proportion of participants achieving clinical remission. | Phase 3 | Recruiting | Drug: Duvakitug, Placebo | Ulcerative Colitis | 980 | 2025-10-08 | 2028-05-09 | in 628 d | 2026-04-24 |
| SNY | Sanofi | — | A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative ColitisNCT06975722Proportion of participants who achieve clinical remission at the end of Week 16 by modified Mayo Score (mMS) | Phase 2 | Recruiting | Drug: SAR442970, Placebo | Ulcerative Colitis | 99 | 2025-07-07 | 2026-12-17 | in 119 d | 2026-04-23 |
| LLY | Eli Lilly and Company | $1.15T | A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)NCT03519945Percentage of Participants in Clinical Remission | Phase 3 | Active, not recruiting | Drug: Mirikizumab | Ulcerative Colitis | 1,058 | 2018-07-18 | 2026-03-04actual | — | 2026-04-20 |
| GILD | Gilead Sciences | $177.9B | Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative ColitisNCT06290934Proportion of Participants Achieving Clinical Response at Week 12 | Phase 2 | Active, not recruiting | Drug: emvistegrast, Placebo-to-match emvistegrast | Ulcerative Colitis | 228 | 2024-03-27 | 2026-03-04actual | — | 2026-04-09 |
| ABBV | AbbVie | $457.5B | A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World SettingNCT07421258observationalPercentage of Participants Managed Using Treat-to-Target (T2T) | — | Recruiting | — | Crohn's Disease, Ulcerative Colitis | 2,000 | 2026-02-09 | Sep 2026 | ≤ 41 d | 2026-03-27 |
| LLY | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | $1.15T | A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UCNCT05291689results2024-11-26Main Cohort: Change From Baseline to Week 12 in the Robarts Histopathology Index (RHI) Score | Phase 2 | Completed | Drug: MORF-057 | Inflammatory Bowel Diseases, Colitis, Ulcerative | 39 | 2022-04-13 | 2023-10-18actual | — | 2026-03-11 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative ColitisNCT05549323Part A: Proportion of participants achieving clinical remission at Week 12 in participants with moderate to severe UC. | Phase 1 | Terminatedsponsor's stated reason: The study was terminated due to business decision. The decision to terminate the trial was not based on any safety concerns associated with PF-07054894. | Drug: PF-07054894, Placebo | Ulcerative Colitis | 44 | 2022-11-07 | 2025-11-11actual | — | 2026-02-25 |
| GILD | Gilead Sciences | $177.9B | Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative ColitisNCT06029972Proportion of Participants Achieving Clinical Response Per Modified Mayo Clinic Score at Week 12 | Phase 2 | Recruiting | Drug: Tilpisertib Fosmecarbil, Placebo | Ulcerative Colitis | 176 | 2023-12-05 | Jan 2027 | ≤ 164 d | 2026-02-11 |
| ODTX | Odyssey Therapeutics | $1.0B | Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative ColitisNCT06850727Change in 3-component modified Mayo Clinic Score (MMCS) from baseline to after treatment with OD-07656 | Phase 2 | Recruiting | Drug: OD-07656, Vedolizumab | Ulcerative Colitis (UC), UC - Ulcerative Colitis | 57 | 2025-06-02 | Apr 2026 | — | 2026-02-11 |
| BMY | Bristol-Myers Squibb | $134.9B | An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical PracticeNCT05369832results2026-02-10Percent of Participants Achieving Clinical Response Measured by Modified Mayo Score for Cohort 1 at Week 12 | Phase 4 | Terminatedsponsor's stated reason: Business objectives have changed. | Drug: Ozanimod | Colitis, Ulcerative | 139 | 2022-12-16 | 2025-01-21actual | — | 2026-02-10 |
| ABBV | AbbVie | $457.5B | Expanded Access to UpadacitinibNCT04159597expanded access | — | Available | Drug: Upadacitinib | Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis | — | — | — | — | 2026-01-30 |
| ABBV | AbbVie | $457.5B | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative ColitisNCT03398135Sub-Study 1: Percentage of Participants Achieving Clinical Remission per Adapted Mayo Score | Phase 3 | Active, not recruiting | Drug: risankizumab, placebo for risankizumab | Ulcerative Colitis (UC) | 1,242 | 2018-08-28 | Sep 2028 | ≤ 772 d | 2026-01-20 |
| PFE | Pfizer | $155.3B | Tofacitinib in Adult Patients With Moderate to Severe Ulcerative ColitisNCT04424303observationalProportion of patients with clinical benefit one year after initiation of tofacitinib treatment. | — | Completed | Drug: Tofacitinib | Ulcerative Colitis | 152 | 2020-12-04 | 2025-12-08actual | — | 2026-01-15 |
| AMGN | Amgen | $229.9B | Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative ColitisNCT04987307results2026-01-13Percentage of Participants With Clinical Remission at Week 12 | Phase 2 | Terminatedsponsor's stated reason: The study was terminated due to meeting a prespecified futility rule and not related to any safety concerns. | Drug: Efavaleukin alfa, Placebo | Ulcerative Colitis | 221 | 2022-01-31 | 2024-10-22actual | — | 2026-01-13 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)NCT03006068Assessing Treatment-Emergent Adverse Events | Phase 3 | Active, not recruiting | Drug: Upadacitinib (ABT-494), Placebo | Ulcerative Colitis (UC) | 950 | 2017-01-31 | Jul 2027 | ≤ 345 d | 2026-01-12 |
| ABBV | AbbVie | $457.5B | Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Events in Adult Participants With Ulcerative Colitis or Crohn's DiseaseNCT06459297observationalPercentage of participants who reported Serious Adverse Event | — | Completed | — | Ulcerative Colitis, Crohn's Disease | 105 | 2024-06-24 | 2025-12-09actual | — | 2026-01-08 |
| ABBV | AbbVie | $457.5B | An Observational Study to Assess Change in Disease Activity and Adverse Events of Rinvoq in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in JapanNCT05791526observationalIncidence Percentage of Serious Infection Reported as Adverse Drug Reaction (ADR) | — | Completed | — | Ulcerative Colitis | 308 | 2022-12-19 | 2025-12-09actual | — | 2025-12-31 |
| ABBV | AbbVie | $457.5B | Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative ColitisNCT05570006results2025-12-23Percentage of Participants Achieving Endoscopic Improvement | Phase 2 | Completed | Drug: ABBV-668 | Ulcerative Colitis | 30 | 2023-03-16 | 2024-12-23actual | — | 2025-12-23 |
| PFE | Pfizer | $155.3B | Generate Real World Data On Tofacitinib Induction Therapy and Changes In Clinical and Patient Reported Outcomes.NCT05069259results2025-04-18observationalPercentage of Participants Who Achieved Clinical Response at Week 8 | — | Terminatedsponsor's stated reason: Study was terminated due to difficulty in enrolling targeted number of participants. There were no safety and/or efficacy concerns in the decision to stop enrollment. | Other: Stool sample collection | Ulcerative Colitis | 18 | 2022-03-28 | 2024-04-30actual | — | 2025-12-19 |
| LLY | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | $1.15T | A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UCNCT05611671results2025-12-15Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS) | Phase 2 | Active, not recruiting | Drug: MORF-057, Placebo | Inflammatory Bowel Diseases, Colitis, Ulcerative | 280 | 2022-11-21 | 2024-11-28actual | — | 2025-12-15 |
| ABVX | Abivax S.A. | — | Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative ColitisNCT03760003results2025-11-28Reduction From Baseline in Modified Mayo Score (MMS) at Week 8 | Phase 2 | Completed | Drug: ABX464 100 mg, ABX464 50 mg, ABX464 25 mg, Placebo | Ulcerative Colitis | 355 | 2019-08-13 | 2021-04-01actual | — | 2025-11-28 |
| ABBV | AbbVie | $457.5B | An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC)NCT06838845observationalAchievement of clinical response per partial adapted Mayo score. | — | Recruiting | — | Ulcerative Colitis | 80 | 2025-04-09 | Dec 2026 | ≤ 133 d | 2025-11-26 |
| TCRX | TScan Therapeutics, Inc. | $107M | A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune DiseaseNCT06587828observationalIdentify peptide targets together with their associated TCRs in patients with autoimmune diseases under study. | — | Recruiting | Procedure: Companion blood samples with procedure | Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma, Ankylosing Spondylitis, Celiac Disease, Non-radiographic Axial Spondyloarthritis (Nr-axSpA), Crohn&Amp;#39;s Disease, Birdshot Chorioretinitis | 300 | 2023-01-03 | Jan 2027 | ≤ 164 d | 2025-11-24 |
| PFE | Pfizer | $155.3B | Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients.NCT06025227expanded access | — | Available | Drug: Etrasimod | Colitis, Ulcerative | — | — | — | — | 2025-11-18 |
| ABVX | Abivax S.A. | — | ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1NCT05507203Proportion of subjects who achieve clinical remission per Modified Mayo Score at week 8 | Phase 3 | Completed | Drug: ABX464, Placebo | Ulcerative Colitis | 639 | 2022-10-10 | 2025-06-24actual | — | 2025-10-24 |
| ABVX | Abivax S.A. | — | ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2NCT05507216Proportion of subjects who achieve clinical remission per Modified Mayo Score at week 8 | Phase 3 | Completed | Drug: ABX464, Placebo | Ulcerative Colitis | 636 | 2022-12-21 | 2025-06-24actual | — | 2025-10-24 |
| ABBV | AbbVie | $457.5B | Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative ColitisNCT02632175results2025-10-16Number of Participants With Adverse Events (AEs) | Phase 3 | Completed | Biological: Adalimumab | Ulcerative Colitis | 59 | 2015-11-26 | 2025-04-08actual | — | 2025-10-16 |
| AMGN | Amgen | $229.9B | Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative ColitisNCT05672199Number of Participants with Treatment-emergent Adverse Events (TEAEs) | Phase 2 | Terminatedsponsor's stated reason: The parent study 20170104 was terminated due to the study meeting a prespecified futility rule. Consequently, this study was terminated. | Drug: Efavaleukin alfa, Placebo | Ulcerative Colitis | 25 | 2023-04-28 | 2024-10-31actual | — | 2025-10-15 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative ColitisNCT06257875Percentage of Participants who Achieve Endoscopic Improvement | Phase 2 | Active, not recruiting | Drug: Lutikizumab, Lutikizumab, Adalimumab | Ulcerative Colitis | 156 | 2024-03-23 | Sep 2027 | ≤ 406 d | 2025-10-07 |
| ANAB | AnaptysBio, Inc. | $1.7B | A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)NCT06127043Mean change in modified Mayo Score (mMs) from Baseline to Week 12 | Phase 2 | Active, not recruiting | Drug: Rosnilimab, Placebo | Ulcerative Colitis | 132 | 2023-12-04 | Jan 2026 | — | 2025-10-03 |
| PTGX | Protagonist Therapeutics, Inc. | $10.2B | Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative ColitisNCT02895100results2021-03-22Proportion of Subjects Receiving PTG-100 With Clinical Remission at Week 12 Compared With Placebo | Phase 2 | Terminatedsponsor's stated reason: Data Monitoring Committee discontinued the trial due to futility-based outcome | Drug: PTG-100, Placebo | Ulcerative Colitis | 98 | Dec 2016 | 2018-03-26actual | — | 2025-08-21 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative ColitisNCT05316220Percentage of Participants Maintaining Clinical Remission Responder Status Based on the modified Mayo Score (mMS) | Phase 3 | Withdrawnsponsor's stated reason: strategic considerations | Drug: Mesalamine, Placebo | Ulcerative Colitis (UC) | 0 | 2025-09-15 | 2026-07-19 | — | 2025-08-12 |
| PALI | Palisade Bio | $356M | Phase 1 Study Evaluating PALI-2108 in Healthy Volunteers and Ulcerative Colitis Patients.NCT06663605Incidence of Treatment-Emergent Adverse Events (TEAE) or abnormal clinical laboratory measure, electrocardiogram (ECG), or vital sign. [ Safety and Tolerability ] | Phase 1 | Completed | Drug: PALI-2108, PALI-2108 Placebo | Ulcerative Colitis (UC), Healthy Volunteer | 89 | 2024-11-05 | 2025-07-07actual | — | 2025-08-07 |
| ABBV | AbbVie | $457.5B | A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)NCT01848561observationalEvaluation of long term safety of Adalimumab in patients with moderately to severely active UC | — | Active, not recruiting | — | Ulcerative Colitis (UC) | 8,250 | 2013-04-29 | Jun 2028 | ≤ 680 d | 2025-07-16 |
| PFE | Pfizer | $155.3B | Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative ColitisNCT04607837results2025-07-15Percentage of Participants Achieving Clinical Remission (CR) at Week 52 Using Modified Mayo Score (MMS) | Phase 2 | Completed | Drug: Etrasimod, Placebo | Ulcerative Colitis | 234 | 2021-04-12 | 2024-06-19actual | — | 2025-07-15 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Utilization, Effectiveness, and Quality of Life of Ozanimod in Participants With Ulcerative ColitisNCT05382715observationalNumber of participants with Clinical Remission, defined by a partial Mayo Score (pMayo) of ≤1 plus an RBS=0 | — | Terminatedsponsor's stated reason: Business objectives have changed | Drug: Ozanimod | Colitis, Ulcerative | 175 | 2022-05-30 | 2025-05-31actual | — | 2025-07-02 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or PsoriasisNCT05796245results2025-06-04observationalIncidence Rate of Serious Infections | — | Completed | — | Arthritis, Rheumatoid, Colitis, Ulcerative, Crohn Disease, Psoriasis | 2,207 | 2023-12-01 | 2024-03-14actual | — | 2025-06-04 |
| LLY | Eli Lilly and Company | $1.15T | An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)NCT03518086results2022-02-28Percentage of Participants With Clinical Remission at Week 12 | Phase 3 | Completed | Drug: Mirikizumab, Placebo | Ulcerative Colitis | 1,281 | 2018-06-18 | 2021-01-21actual | — | 2025-05-31 |
| ABVX | Abivax S.A. | — | Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative ColitisNCT03368118results2025-03-05Number of Treatment-emergent Adverse Events | Phase 2 | Completed | Drug: ABX464 | Ulcerative Colitis | 22 | 2018-01-20 | 2022-07-12actual | — | 2025-05-29 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC)NCT05644665Proportion of participants with clinical remission as measured by the 3-component Mayo Score | Phase 3 | Terminatedsponsor's stated reason: Business objectives have changed | Drug: Ozanimod, Placebo | Ulcerative Colitis | 131 | 2022-12-09 | 2025-03-07actual | — | 2025-03-26 |
| PFE | Pfizer | $155.3B | Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)NCT03884439results2025-03-21observationalNumber of Participants With Adverse Drug Reactions | — | Completed | Drug: Infliximab [infliximab biosimilar 3] | Crohn's Disease, Ulcerative Colitis | 428 | 2019-03-18 | 2024-02-02actual | — | 2025-03-21 |
| ABBV | AbbVie | $457.5B | Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in BelgiumNCT06581042observationalPercentage of Participants Achieving Clinical Remission as per Partial Adapted Mayo Subscores for Ulcerative Colitis | — | Recruiting | — | Ulcerative Colitis, Crohn's Disease | 280 | 2024-09-27 | Sep 2029 | ≤ 1,137 d | 2025-03-05 |
| ABBV | AbbVie | $457.5B | An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World PracticeNCT05494606observationalMedian Time to Achieve the First Clinical Response (CR) per Partial Adapted Mayo Score | — | Active, not recruiting | — | Ulcerative Colitis | 785 | 2022-08-15 | Mar 2028 | ≤ 589 d | 2025-02-28 |
| ODTX | Odyssey Therapeutics | $1.0B | Phase 1 Study to Investigate OD-07656 in Healthy Adult ParticipantsNCT06206811Adverse event assessed by Safety review committee | Phase 1 | Completed | Drug: OD-07656 | Inflammatory Bowel Diseases, Blau Syndrome, Crohn Disease, Ulcerative Colitis, Spondyloarthritis | 101 | 2024-02-12 | 2024-11-25actual | — | 2025-02-21 |
| ABBV | AbbVie | $457.5B | A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative ColitisNCT03398148results2025-01-16Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score | Phase 2/3 | Completed | Drug: risankizumab IV, placebo for risankizumab, risankizumab SC | Ulcerative Colitis (UC) | 1,558 | 2018-03-07 | 2022-11-09actual | — | 2025-01-16 |
| ABBV | AbbVie | $457.5B | Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life ConditionsNCT02738125observationalTime to loss of clinical benefit | — | Completed | — | Ulcerative Colitis (UC) | 265 | 2016-04-29 | 2023-12-15actual | — | 2024-12-31 |
| PFE | Pfizer | $155.3B | Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative ColitisNCT05061446results2024-10-29Percentage of Participants Who Achieved Clinical Remission at Week 12 | Phase 2 | Completed | Drug: Etrasimod, Etrasimod, Placebo | Ulcerative Colitis | 54 | 2021-09-10 | 2023-10-06actual | — | 2024-10-29 |
| PFE | Pfizer | $155.3B | Xeljanz Special Investigation for Long-term Use in UC PatientsNCT03643211results2024-10-08observationalNumber of Participants With Adverse Drug Reactions | — | Completed | — | Ulcerative Colitis | 2,016 | 2018-06-08 | 2022-11-10actual | — | 2024-10-08 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their InfantsNCT06126835observationalPrevalence of major congenital malformations among infants | — | Active, not recruiting | Drug: Ozanimod, Conventional therapy, Advanced therapy | Ulcerative Colitis | 2,828 | 2024-08-26 | 2031-05-31 | in 1,745 d | 2024-10-01 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative ColitisNCT04877990results2024-09-24Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) | Phase 2 | Completed | Drug: Deucravacitinib | Crohn Disease, Ulcerative Colitis | 67 | 2021-05-07 | 2023-08-29actual | — | 2024-09-24 |
| PFE | Pfizer | $155.3B | This Study is to Describe and Evaluate Patients in Finland Treated With Tofacitinib for the Treatment of Ulcerative Colitis Using Real World Data.NCT05082428results2024-09-23observationalAge at the Time of Diagnosis | — | Completed | — | Ulcerative Colitis | 252 | 2022-05-30 | 2022-11-01actual | — | 2024-09-23 |
| PFE | Pfizer | $155.3B | Korea Post-marketing Surveillance for Xeljanz (Registered) in Ulcerative Colitis PatientsNCT04071405results2024-09-03observationalPercentage of Participants With Adverse Events, Adverse Drug Reactions, Serious Adverse Events and Serious Adverse Drug Reactions | — | Completed | Other: Non-intervention | Ulcerative Colitis | 110 | 2020-05-12 | 2022-09-26actual | — | 2024-09-03 |
| BMY | Bristol-Myers Squibb | $134.9B | A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in KoreaNCT06073873observationalAdverse events | — | Recruiting | Drug: Ozanimod | Ulcerative Colitis | 3,000 | 2024-04-19 | 2028-04-01 | in 590 d | 2024-08-22 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative ColitisNCT04613518results2024-07-12Percentage of Participants in Clinical Response at Week 12 | Phase 2 | Completed | Drug: BMS-986165 · Other: Placebo Comparator | Colitis, Ulcerative | 38 | 2021-03-15 | 2023-05-31actual | — | 2024-07-12 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's DiseaseNCT04254783Maximum Observed Plasma Concentration (Cmax) of Midazolam | Phase 1 | Completed | Drug: Risankizumab, Cytochrome P450 (CYP) Substrates | Ulcerative Colitis (UC), Crohn's Disease | 20 | 2020-05-27 | 2022-10-14actual | — | 2024-07-01 |
| ABVX | Abivax S.A. | — | ABX464 in Subjects With Moderate to Severe Active Ulcerative ColitisNCT03093259results2023-02-08Number of Subjects With Treatment-emergent Adverse Events | Phase 2 | Completed | Drug: ABX464, Placebo oral capsule | Ulcerative Colitis | 32 | 2017-11-16 | 2018-07-25actual | — | 2024-06-03 |
| 4151.T | Kyowa Kirin, Inc. | $8.4B | Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative ColitisNCT02647866results2020-03-05Number of Subjects With Treatment-related Adverse Events | Phase 2 | Completed | Drug: KHK4083, Placebo | Ulcerative Colitis, Digestive System Diseases, Colitis, Ulcerative, Colitis, Gastrointestinal Diseases, Inflammatory Bowel Diseases, Intestinal Diseases, Colonic Diseases, Autoimmune Disease, Abdominal Pain | 66 | Jun 2016 | Sep 2018actual | — | 2024-04-26 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)NCT04004611results2023-10-27Pharmacokinetics (PK): Clearance of Mirikizumab | Phase 2 | Completed | Drug: Mirikizumab | Ulcerative Colitis | 26 | 2020-05-18 | 2023-03-15actual | — | 2024-03-26 |
| BMY | Bristol-Myers Squibb | $134.9B | Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative ColitisNCT03934216results2022-07-06Clinical Remission Response Rate at Week 12 | Phase 2 | Completed | Drug: BMS-986165 · Other: Placebo | Ulcerative Colitis | 131 | 2019-07-01 | 2021-06-13actual | — | 2024-03-06 |
| IMUX | Immunic AG | $2.6B | Phase 2 Dose-finding IMU-838 for Ulcerative ColitisNCT03341962results2024-03-05Induction Phase: Symptomatic Remission and Endoscopic Healing at Week 10 | Phase 2 | Terminatedsponsor's stated reason: Considering the efficacy results of the induction phase (allowed use of corticosteroids as concomitant medication) in the study population and since IMU-838 did not show superiority over placebo, the OLE was prematurely closed by the sponsor. | Drug: IMU-838, Placebo | Ulcerative Colitis | 263 | 2018-03-15 | 2022-11-16actual | — | 2024-03-05 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Ulcerative Colitis is matched — 8 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Ulcerative Colitis
- Ulcerative Colitis (UC)
- Colitis, Ulcerative
- Ulcerative Colitis Chronic
- Moderate to Severe Ulcerative Colitis
- Ulcerative Colitis Chronic Moderate
- Ulcerative Colitis, Active Moderate
- Ulcerative Colitis, Active Severe
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Ulcerative Colitis” (a text search, wider than this page)